Histogenics (NASDAQ:HSGX) target price reduced to $8.00, reported today by Needham
- Updated: September 18, 2016
Indicating a possible upside of 1.49%, Needham lowered the target price of Histogenics (NASDAQ:HSGX) to $8.
Showing a price of $3.21, Histogenics (NASDAQ:HSGX) traded 6.69% lower on the day. With the last stock price up 41.33% from the two hundred day average, compared to the S&P 500 which has fallen -0.01% over the same time period. The company has recorded a 50-day average of $2.72 and 200-day moving average of $2.27. 131,378 shares of HSGX exchanged hands, up from ann average trading volume of 47,605
Histogenics has a one-year low of $1.39 and a one-year high of $6.24 and has a market capitalization of $0.0.
General Company Details For Histogenics (NASDAQ:HSGX)
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, and the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.